請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55220
標題: | 設計合成與評估8-甲氧基喹啉衍生物作爲抗阿茲海默症之潛在多靶點藥物 Design, Synthesis and Evaluation of 8-Methoxyquinoline Derivatives as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease |
作者: | Qing-Qing Ye 葉青青 |
指導教授: | 陳基旺 |
關鍵字: | 阿茲海默症,多靶點藥物,??衍生物, Alzheimer’s Disease,Multifunctional Agents,Quinoline Derivatives, |
出版年 : | 2014 |
學位: | 碩士 |
摘要: | The aim of this thesis is to design and synthesize novel series of 8-methoxyquinoline derivatives based on lead compound J2326, which targets and modulates multiple facets of Alzheimer’s disease (AD). The J2326 was designed and synthesized previously in our lab by merging two compounds, namely neurotrophic n-hexacosanol and metal-chelating clioquinol, which blocked metal-induced fAβ formation. A series of 8-methoxyquinoline-2-yl-alkyl derivatives was designed by introduction of hydroxyl, carbonyl, oxime moieties at α position on the side chain of J2326 to improve its solubility and metal chelation activity profile. Benzylic oxidation of appropriate 8-methoxy-2-methylquinoline afforded respective 8-methoxy-2-aldehyde-quinoline, which on Grignard reaction with dec-9-en-1-ylmagnesium bromide afforded corresponding alkene-alcohol, with side chain bearing terminal olefin. This terminal olefin was then converted to hydroxyl group by hydroboration oxidation reaction to afford first series of target molecules (TM). Further, the α-hydroxyl moiety of these molecules was converted to carbonyl by selective oxidation of secondary alcohol to afford second series of TM. These ketones were then converted to oximes by reaction with hydroxylamine hydrochloride to afford third series of TM. The biological evaluation of these 8-methoxyquinoline derivatives demonstrated that all compounds retained metal chelating as well as neurotrophic activities as that of J2326. Among these, compounds with oxime and secondary alcohol at α position were found better than carbonyl for anti-fAβ and neurotrophic activities. Structure-activity relationship (SAR) study led to identification of novel leads oxime 6c, 6d and 6f with 5’-F, 5’-CF3 and 6’-F substituted which were more effective than J2326. Interestingly, most compounds have much better solubility profile (0.6-87.7μg/ml) than J2326 (<0.003 μg/ml). Furthermore, these compounds showed anti-ROS activity and acceptable blood-brain barrier permeability profile. Compound 6c, 6d, 6f and 6h can serve as leads for further optimization to develop a potential candidates for AD treatment. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55220 |
全文授權: | 有償授權 |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 6.08 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。